Hookipa Pharma Inc (NASDAQ:HOOK – Get Rating) – Investment analysts at SVB Leerink lifted their Q2 2022 earnings per share estimates for Hookipa Pharma in a research note issued on Monday, May 16th. SVB Leerink analyst A. Berens now expects that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.70). SVB Leerink has a “Outperform” rating and a $4.00 price objective on the stock. SVB Leerink also issued estimates for Hookipa Pharma’s Q3 2022 earnings at ($0.39) EPS, Q4 2022 earnings at ($0.34) EPS, FY2022 earnings at ($1.47) EPS, FY2023 earnings at ($1.13) EPS, FY2024 earnings at ($1.11) EPS, FY2025 earnings at ($1.01) EPS and FY2026 earnings at ($0.66) EPS.
Hookipa Pharma (NASDAQ:HOOK – Get Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.28). Hookipa Pharma had a negative net margin of 523.54% and a negative return on equity of 70.82%. During the same period in the prior year, the firm earned ($0.53) EPS.
Other research analysts have also recently issued research reports about the stock. Truist Financial cut their target price on shares of Hookipa Pharma from $23.00 to $16.00 in a research note on Wednesday, February 16th. Zacks Investment Research downgraded Hookipa Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, February 10th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Hookipa Pharma in a report on Friday, March 25th. Finally, Royal Bank of Canada lowered their target price on Hookipa Pharma from $11.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, March 25th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $7.93.
Shares of HOOK stock opened at $1.54 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.69 and a quick ratio of 3.69. Hookipa Pharma has a 12-month low of $1.25 and a 12-month high of $19.49. The firm has a 50-day moving average price of $1.68 and a 200 day moving average price of $2.27.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOOK. Parametric Portfolio Associates LLC bought a new stake in shares of Hookipa Pharma during the fourth quarter worth $44,000. Banque Cantonale Vaudoise acquired a new stake in Hookipa Pharma in the first quarter worth about $46,000. LPL Financial LLC bought a new stake in Hookipa Pharma during the 3rd quarter worth about $62,000. HighVista Strategies LLC acquired a new position in Hookipa Pharma during the 3rd quarter valued at about $71,000. Finally, Barclays PLC boosted its stake in shares of Hookipa Pharma by 94.4% in the 4th quarter. Barclays PLC now owns 31,822 shares of the company’s stock valued at $74,000 after purchasing an additional 15,454 shares during the last quarter. 57.65% of the stock is owned by institutional investors.
Hookipa Pharma Company Profile (Get Rating)
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Receive News & Ratings for Hookipa Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hookipa Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.